Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of doxorubicin + trabectedin as first-line therapy for metastatic or unresectable recurrent leiomyosarcoma
2009-012430-70Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- May 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin and doxorubicin in leiomyosarcoma (LMS) and uterine leiomyosarcoma (uLMS), sponsored by Gustave Roussy. Primary endpoint: Disease control rate. Started May 2009; status: completed.
02
Drugs
trabectedindoxorubicin
03
Conditions
leiomyosarcoma (LMS)uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on 2009-012430-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012430-70.